This study investigated classical conditioning in women undergoing outpatient adjuvant chemotherapy for breast cancer. Breast cancer chemotherapy outpatients were randomly assigned either to an Experimental Group (exposed to a distinctive stimulus before each infusion of chemotherapy) or to a Control Group. After repeated infusions of chemotherapy, patients' responses to the experimental stimulus were assessed in a location not associated with chemotherapy. Experimental Group patients had increased nausea (self-reported on a visual analog scale) following the presentation of the experimental stimulus at this test trial, whereas Control Group patients did not. Two other measures of nausea corroborated these results. Post hoc statistical analyses confirmed predictions based on conditioning theory. This conditioning model of anticipatory nausea bears witness to the relevance of classical conditioning in clinical medicine.
INTRODUCTION
In addition to the well known sideeffects of nausea and vomiting after chemotherapy infusions, between 25% and 57% (depending upon the particular regimen of cytotoxic agents) of cancer patients come to experience nausea in anticipation of treatment infusions (1) . Chemotherapy treatment typically involves cycles of intravenous treatment over a several-week interval and the probability of anticipatory nausea increases with repeated cycles (1, 2) . After even one experience of post-treatment nausea, some patients experience anticipatory nausea as they await subsequent treatment infusions (1, 2) . Despite continuing improvements in available antiemetic treatments (3), anticipatory nausea and vomiting continues to be a significant clinical problem, having an impact on quality of life as well as compliance with treatment (4) .
Researchers have argued that anticipatory nausea is best understood in terms of classical conditioning (1, 2, 5, 6) . According to this view, anticipatory nausea is a conditioned response to one or more distinctive features of the chemotherapy
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clinic (conditioned stimuli) associated with the administration of emetogenic chemotherapy (unconditioned stimulus), relatively independent of patients' expectations of imminent chemotherapy treatment. Because of ethical and practical limitations, support for the conditioning explanation has been based solely on correlational studies. These studies have been limited to investigation of the relations between patient characteristics, treatment variables, and the occurrence of anticipatory nausea and vomiting (1, 2, 4-6).
The present study was designed as a first experimental test of the hypothesis that patients undergoing repeated chemotherapy can develop classically conditioned nausea. By experimentally examining conditioned nausea responses in cancer patients, the present study could provide a model of anticipatory nausea and further our understanding of classical conditioning in humans. Our strategy for this experimental approach was to pair a distinctive stimulus with each infusion of chemotherapy and then to assess patient response to that stimulus presented alone in a location not associated with chemotherapy. Nausea in response to presentation of the experimental stimulus would support the hypothesis that patients had developed conditioned nausea. The conditioning hypothesis would be further supported if the intensity of patients' nausea responses to the experimental stimulus were related to the pattern and intensity of post-infusion nausea, the putative unconditioned response, in ways predicted by conditioning theory.
METHODS

Overview
Breast cancer patients scheduled for adjuvant chemotherapy treatment were randomly assigned to two groups, one of which was exposed to a distinctive stimulus (a beverage) in the clinic before each infusion (Experimental Group), while the other was not exposed to the distinctive stimulus in the clinic [Control Group). According to the conditioning hypothesis, each chemotherapy infusion thus served as a "conditioning trial," for the Experimental Group; a conditioned stimulus (the distinctive beverage) was paired with an unconditioned stimulus for nausea (infusion of emetogenic chemotherapy). According to the conditioning hypothesis, the assessment of responses to the beverage presented by itself in an environment not associated with chemotherapy (each patient's home) served as a "test trial" for the Experimental Group; patients were exposed to the conditioned stimulus (the beverage) and conditioned responses (nausea) assessed in the absence of the unconditioned stimulus and unconditioned response (nausea).
We chose to use a distinctive beverage as the experimental conditioned stimulus for three reasons. First, it was convenient to use a beverage. Exposure to the beverage stimulus before each infusion could be kept under tight experimental control with little difficulty or expense (unlike having a distinctively decorated chemotherapy suite, for example). Exposure to the stimulus alone (not followed by an infusion) for testing of the putative conditioned response could be easily accomplished at a location not associated with chemotherapy, thus avoiding the confounding effects of other possible conditioned stimuli. Second, because previous studies of anticipatory nausea have indicated that a wide variety of stimuli associated with chemotherapy (e.g., the nurse's perfume, the color of the drugs, the sight of the oncologist) can elicit nausea in patients (6) we wanted an experimental item that would stimulate a number of sensory modalities, including sight, smell, touch, and taste. We therefore selected a beverage that was distinctive in color, in odor, as well as in taste, and provided it to patients in a distinctive cup (see below). Third, from a teleological perspective, we speculated that a conditioned nausea response might be more readily acquired to taste stimuli because gustatory cues might be more effective stimuli for nausea responses than other kinds of stimuli. As yet, there is no evidence that taste stimuli are particularly salient for the development CONDITIONED NAUSEA DURING CHEMOTHERAPY of conditioned nausea responses, but a large research literature with experimental animals (7, 8) indicates that conditioned aversions are more readily established to tastes and smells than to other types of stimuli (e.g., distinctive places). There have also been experimental reports that patients undergoing chemotherapy for cancer can develop conditioned aversions to food/beverage items paired with chemotherapy (9) (10) (11) (12) (13) (14) (15) . Such aversions could, of course, have proved detrimental to our investigation of conditioned nausea responses by compromising the repeated pairing of the beverage with chemotherapy infusions (e.g., if patients refused to taste the beverage in the clinic, the contingency with chemotherapy would be reduced). Therefore, after a patient had undergone a minimum of three infusions, she was scheduled for a home assessment of nausea responses to the beverage when she reported disliking the beverage (see below).
Patients' responses to the beverage were assessed by an unfamiliar research assistant in each patient's home to eliminate the potential confounding effects of patients' expectations of imminent chemotherapy and possible conditioned responses to other stimuli associated with the chemotherapy clinic.
Patients
Seventy-eight women were recruited from 88 consecutive patients scheduled for outpatient IV chemotherapy for breast cancer, as part of a larger research project addressing biobehavioral side effects of cancer treatment. The study was approved by the Institutional Review Board at Memorial Sloan-Kettering Cancer Center and written informed consent was obtained prior to participation. The following selection criteria were used: a) women diagnosed with Stage I or II breast cancer, status post-radical, modified radical, or segmental mastectomy; b) Karnofsky performance status over 70; c) no chemotherapy prior to present protocol; d) not scheduled for radiation during chemotherapy; e) 18 years of age or older; f) not currently pregnant; g) no current or previous neurological or psychiatric disorders; h) no concurrent neoplasm or immunological illness; l) no diabetes mellitus; j) live within 2 hours of New York City; k) English speaking; and 1) no hearing impairment.
Of the 88 patients approached, 78 (89%) agreed to participate in the larger research project (the most common reason for refusal was that they were already overburdened by the treatment). Fourteen patients (18%) dropped out of the study prior to completion for the following reasons: feeling overburdened (N = 10: Experimental Group: N = 5; Control Group: N = 5); illness complications (N = 1); scheduling conflicts (N = 2); and one patient was excluded due to accidental pre-exposure to test stimuli. Seventeen patients (22%) (Experimental Group: N = 6; Control Group: N = 11) refused to participate in the assessment of the conditioned response because they felt uncomfortable with having research personnel come to their homes. Thus, 47 patients were included in the study reported here.
All patients received intravenous (IV) chemotherapy on an outpatient basis every 3 or 4 weeks for an average of eight infusions of standard chemotherapy combinations. None of the subjects in the present study received oral chemotherapy. Review of medical records (confirmed by pharmacy records) indicated that patients were treated with cycles of chemotherapy agents in the following standard combinations All patients received a standard regimen of IV antiemetic medications at each infusion, including dexamethasone (10-40 mg) and lorazepam (0.5-2.0 mg), unless one of these medications was contraindicated by the patient's medical condition. This regimen of antiemetic medication was modified only as clinically necessary on an individual basis by each patient's attending oncologist to add one or more of the following: prochlorperazine (10 mg), metoclopramide hydrochloride (40-100 mg), ondansetron (0.15 mg/kg), or diphenhydramine hydrochloride (25-50 mg). There were no significant differences between the two study groups in doses (t tests) or antiemetic agents used (Chi square analyses).
At recruitment, all patients were told that the purpose of the study was to investigate the development of chemotherapy side effects over the course of repeated cycles of treatment. In order to reduce the possible influence of demand characteristics (16), patients were not informed that the study would 
Procedure
Experimental Group (N = 25): Patients in this group received a distinctive beverage, lemon-lime Kool-Aid (Kraft General Foods Inc., White Plains, NY) (13) , in the outpatient clinic prior to each infusion of chemotherapy. Patients were instructed to drink as much as they wished (up to the entire 150 ml offered) from the 8-ounce sterile cup (Corning, Corning NY). Patients generally liked the beverage, as suggested by: a hedonic rating (see below) prior to the first infusion of 6.1 + 0.4 (mean ± SE), and by an initial beverage consumption of 79.6 ± 9.3 ml Patients also completed standardized questionnaires (see below) as they awaited each chemotherapy infusion.
Post-chemotherapy nausea (the putative unconditioned response) was routinely assessed with standard telephone questionnaires as soon as patients could be contacted, but never earlier than 2 days following treatment (mean = 5 days). This procedure was repeated following each chemotherapy infusion. At the assessment prior to the third infusion, if a patient's hedonic rating of the beverage was three or less ("Dislike moderately" to "Dislike very much" on the nine-point scale), she was scheduled for a home assessment of her response to the beverage. The home assessment (see below) was scheduled for approximately 3 days prior to her next infusion, or (for patients whose hedonic ratings were never three or below) approximately 3 weeks after the final infusion. We chose this time to minimize the likelihood that continuing post-chemotherapy nausea would be present and therefore confound assessment of the response to the beverage.
Conlrol Group (N = 22). Procedures were identical to those of the Experimental Group, except patients were not given the beverage in the clinic. Home assessments were yoked to the Experimental Group to match chemotherapy protocol and number of previous infusions
Measures
InilinJ Assessment As in our previous studies of chemotherapy side effects (17) , all patients completed a standard demographic questionnaire and the Bendig short-form of the Taylor Manifest Anxiety Scale (TMAS), a self-report measure of general anxiety level (18) . Patients also completed a History of Nausea and Vomiting Questionnaire (HNVQ). which assesses nausea or vomiting in reaction to nine common emetogenic situations (e.g., motion, anxiety, pregnancy); the HNVQ score is reported as the total number of positive items (17) .
Pre-In/usion Assessment. Before each infusion patients completed a nine-item symptom checklist (e.g., nausea, skin itching, hair loss). Patients indicated the presence or absence of these for the prior 24-hour period. The goal was to ascertain the presence of nausea without sensitizing the patient to its development (17) . If nausea was reported, the intensity was assessed separately with a visual analog scale (19, 20) .
Patients in the Experimental Group also completed a nine-item beverage questionnaire immediately after receiving the beverage. Subjects characterized and rated the smell and taste of the beverage on nine-point Likert scales. The hedonic rating of the beverage was a single item on the questionnaire asking for: "current preference for the beverage" with five of the nine points on this scale labeled (1 = Dislike very much, 3 = Dislike moderately, 5 = Neither like nor dislike, 7 = Like moderately, 9 = Like very much), as described by Andrykowski and Otis (21) Pos(-In/usion Assessment. As in our previous studies, post-chemotherapy side effects were assessed by a telephone interview questionnaire following each infusion (22) . Patients were asked if they had experienced any of the following side effects of chemotherapy in the 24 hours after the infusion: nausea, vomiting, change in taste or appetite, feeling tired, hair loss, skin itching, pain, weakness, diarrhea, chills, or nervousness. If nausea was reported, patients were asked to rate its intensity on a scale of 0 to 100. The internal consistency of this assessment was found to range from 0.64 to 0.77 across six infusions (22) .
Home Assessment. Prior to beverage presentation, all patients listed any drugs they had taken in the previous 3 days and completed the symptom checklist for their experience "in the last 24 hours." Patients then provided separate visual analog scale ratings of anxiety and of nausea for three points in time: a) "last night." b) "this morning," and c) "right now." After being offered the beverage, patients immediately completed the beverage questionnaire, the symptom checklist, and provided visual analog scale ratings of nausea for "right now." Of particular interest was their response on the beverage ques-CONDITIONED NAUSEA DURING CHEMOTHERAPY tionnaire to the item assessing feelings the beverage evoked (labeled at five of nine points: 1 = It makes me feol great, 3 = It calms my stomach, 5 = It has no effect. 7 = It makes me feel queasy, 9 = It makes me feel nauseated).
RESULTS
Demographic Characteristics
Demographic characteristics of the Experimental and Control groups are shown in Table 1 . Despite randomization, the Experimental and Control groups differed in age, with the Experimental group being significantly younger. There were no other significant demographic differNausea Responses to the Beverage Patients who received the beverage paired with chemotherapy (Experimental Group) reported more nausea to the beverage at the home assessment than Control Group patients on each of the three measures of nausea response: a) the visual analog scale rating of nausea; b) the rating of how the beverage made patients feel; and, c] the symptom checklist indication of nausea. These results were consistent with the hypothesis that patients developed a conditioned nausea response to the beverage paired with chemotherapy infusions. First, visual analog scale ratings of nausea before and after presentation of the beverage in patients' homes (see Figure 1 ) revealed significant differences between the Experimental and Control Groups after the presentation of the beverage. Repeated measures ANOVA over the two points of assessment (immediately before and after the beverage) indicated a signif- Second, nausea responses to the beverage in the Experimental Group were also evident in patients' answers to: "How does the beverage make you feel?" Responses tending toward "It makes me feel nauseated" were found in Experimental Group (Mean = 6.5) compared to the Control group, whose responses tended toward "It has no effect" (Mean 4.8), t(41.52) = 4.67, p < 0.0001.
Third, when patients were asked simply to indicate on a checklist of symptoms whether or not they were experiencing nausea after the presentation of the beverage, differences between the groups were again evident. Only one of 22 patients in the Control Group reported nausea on this measure, while seven of 25 patients in the Experimental Group reported nausea (Fisher's Exact Test: p < 0.05). No significant differences were found in patients' reported experiences of nausea in the 24 hours prior to the beverage presentation.
It is of interest to note that the three different measures used for assessment of nausea responses to the beverage all revealed significant differences between the Groups. However, the incidence of nausea responses in the Experimental Group differed somewhat from measure to measure. On the visual analog scale rating of nausea, nine out of 25 patients (36%) had scores greater than zero following the beverage presentation; on the beverage questionnaire, 12 out of 25 patients (48%) rated the beverage at seven or higher (from, "It makes me feel queasy" to "It makes me feel nauseated"); while, on the symptom checklist seven out of 25 patients (28%) checked off nausea as a symptom they experienced after the beverage presentation. The higher incidence on the beverage questionnaire could reflect the broader definition used; the lower incidence on the checklist may reflect a tendency for patients to be consistent across measurements collected within a short time span.
Was the Nausea Response to the Beverage Due to Group Differences Independent of the Experimental Manipulation?
Although patients were randomly assigned to Experimental and Control Groups, we explored the possibility that differences in psychobiological characteristics could have existed between the two groups. As shown in Table 2 , no significant differences between the groups were found. Since no patients reported taking any antiemetics or anxiolytics on the day of the home assessment, or over the three previous days, these data were not included in the table. Did Differences in Post-Chemotherapy Nausea Predict Nausea Responses to the Beverage in the Experimental Group? Although some patients in the Experimental Group reported extremely intense nausea responses to the beverage (e.g., visual analog scale rating of 100, postbeverage), others reported less intense nausea, or no nausea at all. According to classical conditioning theory, variability in that response should be predicted by variability in patients' post-treatment nausea (the putative unconditioned response). We carried out post hoc statistical analyses to examine two possibilities. First, because conditioning is reduced by exposure to a conditioned stimulus prior to pairing it with the unconditioned stimulus, a phenomenon termed latent inhibition (23, 24), conditioned nausea should be weaker in patients whose first experience with the beverage (infusion one) was not followed by nausea. Second, the nausea response to the beverage should be stronger in patients with more intense post-chemotherapy nausea (25) . (Note: for the analyses below, N = 23, as data for nausea following the first infusion were unavailable for two patients).
CONDITIONED NAUSEA DURING CHEMOTHERAPY
To explore the possible influence of latent inhibition, we correlated patients' nausea responses to the beverage (visual analog scale, post-beverage) with their nausea report (present or absent) following the first chemotherapy infusion. Postchemotherapy nausea report at infusion one was significantly correlated with nausea response to the beverage (r = 0.51, p = 0.017).
A possible effect of latent inhibition on the nausea response to the beverage was supported by a second analysis, which focused on the incidence of the nausea response to the beverage ( hibition could thus account for about two thirds (9/15) of the patients who did not develop a nausea response to the beverage (N = 15). Indeed, a nausea response to the beverage was only seen in patients who had experienced nausea following the initial infusion. These results are consistent with latent inhibition.
To explore the relation between the intensity of patients' post-chemotherapy nausea (putative unconditioned response) and subsequent nausea responses to the beverage (visual analog scale post-beverage), another analysis was conducted. The mean post-infusion nausea rating across all infusions prior to the home assessment for each patient in the Experimental Group was correlated with the nausea response (visual analog scale) to the beverage (r = 0.47, p = 0.02). Because this calculation of the mean post-infusion nausea response included the data from the first infusion, the apparent relation between the putative unconditioned response and the nausea response to the beverage was confounded by a putative influence of latent inhibition. We therefore excluded nausea following the first infusion from the calculation of the mean post-chemotherapy nausea; the relation between the putative unconditioned nausea response and the nausea response to the beverage was no longer significant (r = 0.34, p = 0.13).
To directly examine the relative contribution of possible latent inhibition (nausea following the first infusion, yes/no) and mean post-infusion nausea (excluding the first infusion) to the nausea response to the beverage, we entered these two variables simultaneously into a regression analysis. This model (with both variables entered together) accounted for a significant amount of the variance in the nausea response to the beverage (R 2 = 0.29, p = 0.049). Nausea following the first infusion was significantly related to the nausea response to the beverage when controlling for the mean post-infusion nausea responses (beta = 0.44, t = 2.07, p = 0.053). On the other hand, the mean post-infusion nausea response was not significantly related to the nausea response to the beverage when controlling for nausea following the first infusion (beta = 0.18, t = 0.87, p = 0.40). These results should be interpreted with caution; although regression analyses are relatively robust to influences of multicollinearity (26), there was a tendency for the two predictor variables to be related (r = 0.35, p = 0.12).
Did the Nausea Response to the Beverage Relate to Either the Beverage Hedonic Rating or to the Amount of Beverage Consumed in the Experimental Group? To explore the relations between the intensity of patients' nausea responses to the beverage (visual analog scale, postbeverage) and their hedonic rating of the beverage, we conducted Pearson correlations with both the preference rating (nine point scale) and the amount of beverage consumed (out of 150 ml offered). Patients' hedonic ratings of the beverage at the home assessment were related to their nausea responses to the beverage (visual analog scale) (r = -0.46, p = 0.02). The reduction in hedonic rating from the first assessment (prior to chemotherapy) to the home assessment was also related to the nausea response to the beverage (r = -0.62, p = 0.001).
To further examine the relations between the nausea response to the beverage and the hedonic rating, we compared the incidence of nausea among the patients in the Experimental Group with the numbers of patients meeting criteria for low hedonic rating. As reported above, nine out of 25 patients (36%) had a nausea response to the beverage (visual analog scale > 0) at the home assessment. We considered hedonic ratings (nine point scale) from three different perspectives: First, considering the absolute rating, 20 out of 25 patients (80%) rated the beverage between 1 and 3 ("Dislike very much" to "Dislike moderately"); second, considering any reduction in hedonic rating, 22 out of 25 patients (88%) had a lower rating for the beverage at the home visit than at the first presentation of the beverage (prior to chemotherapy); and third, considering a strong reduction in rating, 12 out of 25 patients (48%) had a reduction in hedonic rating of four or more points between the first presentation and the home assessment.
A reduction of four or more points on the hedonic scale has been used as a criterion for "taste aversion" by some authors (21) . It should be noted that, of the 12 out of 25 patients meeting this criterion in the present study, only seven had a nausea response to the beverage. On the other hand, of the nine out of 25 patients with a nausea response to the beverage, two did not meet this criterion for having a "taste aversion" to the beverage. Moreover, the mean beverage hedonic rating (1.4 ± 0.3) of the nine patients with a nausea response to the beverage was not significantly different from the mean ratings (2.1 ± 0.3) of the 16 patients without nausea responses to the beverage (t(18) = 1.57, p = 0.13). These results suggest that patients' hedonic ratings were related to their experience of nausea to the beverage, but taste aversion was neither necessary nor sufficient to account for the nausea response.
With regard to beverage consumption, nausea responses to the beverage were not significantly correlated with the amount consumed at the home assessment (r = -0.33, p = 0.11), or with the reduction in consumption between the first assessment and the home assessment (r = -0.29, p = 0.17). Interestingly, of the nine out of 25 patients who had a nausea response to the beverage, four (of the nine) refused to taste the beverage; one (of the four) even refused to smell it. One out of the 16 patients without a nausea response to the beverage refused to taste the beverage.
DISCUSSION
The results of the present experiment support the classical conditioning hypothesis that the pairing of a distinctive stimulus with chemotherapy results in the development of a conditioned nausea response. The patients randomly assigned to receive a distinctive beverage in the clinic prior to each infusion (Experimental Group) later experienced more nausea when the beverage was presented alone, than patients who were not given the beverage with chemotherapy (Control Group). The significant difference between the groups was evident on each of three separate measures of nausea response to the beverage.
In this discussion we begin by reviewing the evidence supporting the hypothesis that the nausea response to the beverage was the result of classical conditioning. Next we consider the relevance of our findings to research on anticipatory nausea and vomiting, as well as to clinical practice. Finally, we explore the contribution of these findings to the literature on human classical conditioning.
Of central importance to the current study is the role of classical conditioning. The significant difference between the Experimental and Control Groups in nausea following beverage presentation is consistent with the hypothesis that the pairing of a distinctive stimulus with infusions of chemotherapy results in the establishment of a conditioned nausea response. We found no support for nonconditioning explanations for the group differences in nausea response to the beverage. The only variable on which the two groups were found to differ was age, which statistical analysis indicated did not account for the differences in nausea response to the beverage.
The groups did not differ in nausea ratings immediately before the beverage presentation at the home assessment. However, a few patients in each group did report nausea at that moment. There are several possible explanations. For patients in the Control Group, one can rule out the possibility that they were anticipating the beverage, because their nausea was not increased after the beverage presentation. It is unlikely that lingering postchemotherapy nausea accounted for the results, because the home visit took place several weeks after treatment and clinical research indicates that post-infusion nausea generally is resolved within hours or at most days (27, 28) . A more provocative possibility is that some patients may be unusually sensitive to thoughts of chemotherapy and feel nauseated when simply reminded of their experiences by the arrival of the research interviewer at their homes. We have recently found that patients with a history of anticipatory nausea become nauseated when they immerse themselves in thoughts and images of chemotherapy treatment (29) .
Further support for the conditioning hypothesis was provided by post hoc statistical analyses of the relations between patients' experiences of post-chemotherapy nausea (putative unconditioned response) and the magnitude of their nausea responses to the beverage (putative conditioned response). Consistent with our previous results indicating that the intensity of post-chemotherapy nausea predicts the development of anticipatory nausea (17), we found that patients in the Experimental Group with more intense postchemotherapy nausea across all infusions prior to the home assessment had a stronger nausea response to the beverage. Interestingly, we found that if we excluded nausea following the first infusion from the calculation of mean post-infusion nausea, the relation was no longer significant.
Additional post hoc statistical analyses indicated a significant correlation between patients' experiences of nausea following the first infusion and their nausea responses to the beverage. This correlation was significant even when we statistically controlled for patients' average levels of post-infusion nausea (excluding Infusion 1). The importance of the nausea rating following the first experience of the beverage and chemotherapy (Infusion 1), is consistent with the conditioning phenomenon of latent inhibition, well documented in the animal literature (23). In animal models, pre-exposure to a stimulus prior to its being paired with an unconditioned stimulus results in "latent inhibition" (i.e., reduced levels of conditioned responses in the preexposure group). A post hoc examination of the data in the present study indicated that unless patients experienced nausea after their CONDITIONED NAUSEA DURING CHEMOTHERAPY first exposure to the beverage (Infusion 1] they did not show a nausea response to the beverage at the home assessment. Consistent with latent inhibition, nausea following the first infusion appeared to be necessary (but not sufficient) for the occurrence of nausea responses to the beverage at the home assessment. An experimental study of latent inhibition is necessary, of course, to rule out the possibility that uncontrolled confounding variables could account for the apparent effects of latent inhibition in the current study.
Demand characteristics (16) of the study could conceivably have induced patients to report nausea after the beverage when, in fact, they were not experiencing nausea. We reduced this likelihood in two ways: a) by not telling patients that conditioning was expected, and b) by not revealing patients' group assignments to the home assessment technician. Nevertheless, some patients may have surmised the conditioning hypothesis of the study and decided to provide us with confirmatory evidence. However, it seems highly unlikely that these patients would have had the understanding of classical conditioning necessary to adjust their responses to the beverage to provide results consistent with latent inhibition.
The significant correlation between patients' hedonic ratings of the beverage and their nausea responses to the beverage was also consistent with the hypothesis that conditioning processes were responsible for the nausea response, because taste aversions (reduced hedonic ratings) to food items paired with chemotherapy have been established as conditioned responses in several previous experimental studies (9) (10) (11) (12) (13) (14) (15) . The role of nausea (as an unconditioned response) in the development of conditioned taste aversion remains controversial (8, 30) . However, it is reasonable to suggest that patients' reduced hedonic ratings and their nausea responses to the beverage may be related to one another through their relation to patients' experiences of post treatment nausea (putative unconditioned responses).
The results of this study are consistent with the possibility that two conditioned responses to the beverage developed as a result of the pairing with chemotherapy: a conditioned aversion and a conditioned nausea response. The possibility that multiple conditioned responses can develop following the pairing of a distinctive beverage with cytotoxic chemotherapy agents has been supported in animal experiments (31) . Indeed, multiple conditioned responses to stimuli paired with pharmacologic agents have proven to be more the rule than the exception in animal models (32) .
We found that the correspondence between nausea responses to the beverage at the home assessment and the beverage hedonic rating was not one to one. Most notably, more patients showed evidence of reduced hedonic ratings for the beverage than showed nausea responses to the beverage. Although one can always raise questions concerning the adequacy of assessment instruments, our results did not support the view that a conditioned nausea response underlies every experience of taste aversion. To the contrary, the results suggest that conditioned taste aversion may be a more robust phenomenon than conditioned nausea. The possibility that conditioned taste aversions develop more readily than conditioned nausea responses is consistent with a hierarchical view of innate defense mechanisms adaptive for protection against toxins (33); avoidance is considered the first line of defense, followed by nausea, and then by vomiting.
Our data did not support the view that the nausea response could only be triggered by gustatory cues; several patients refused to taste, one even to smell, the beverage at the home assessment but nonetheless reported nausea after the beverage presentation. These findings suggest that other aspects of the beverage (e.g., the color) could also elicit nausea responses. Support for the possibility that a wide range of stimuli can serve as conditioned stimuli for nausea is readily found in the literature on anticipatory nausea. Nausea in the clinic as patients await chemotherapy has been reported to be triggered by a wide range of non-gustatory stimuli, including a glimpse of the physician who previously administered treatment (34) . The relative salience of taste cues compared to other types remains to be addressed in future experimental research on conditioned nausea.
The study reported here provides a conditioning model of anticipatory nausea, which should both stimulate and facilitate future research. Past research on anticipatory nausea has been hampered by the idiosyncratic nature of the stimuli that elicit anticipatory nausea, and compromised by the potential confounds of correlational approaches. With the increased predictability afforded by a conditioning model of anticipatory nausea, investigators may be better able to explore the physiological mechanisms underlying anticipatory nausea responses and to test novel strategies for treatment.
There may be more immediate implications of the results of the present study for clinical practice. Complementing previous clinical studies indicating that antiemetic treatment for post-chemotherapy nausea is most effective if begun prior to any experience of nausea (35) , our data suggest that effective antiemetic treatment before the first infusion may prove critical for blocking the development of conditioned nausea. In light of that possibility, clinical studies should examine the potential utility of exposing patients to the clinic on a day before their chemotherapy is administered, to reduce the development of conditioned nausea to those stimuli. At the same time it may be helpful to provide a distinctive cue (e.g.. the beverage) before chemotherapy. Our initial data suggest that to the extent that the beverage becomes a conditioned stimulus for nausea, it serves as a "scapegoat" and reduces conditioned nausea responses to other clinic stimuli. This scapegoat effect has previously been reported to be effective in reducing the development of learned food aversions during chemotherapy (13, 36, 37) .
The results presented here are also pertinent to renewed interest in human classical conditioning (38, 39) . Following our findings analyzing conditioned nausea responses in chemotherapy patients, future studies should consider experimentally eliminating potential confounds by use of a within-subjects conditioning design (40) . Following this approach, the nausea response of a beverage paired with chemotherapy (conditioned stimulus-!-) could be compared to a beverage not paired with chemotherapy (conditioned stimulus-)' Although presentation of the conditioned stimulus-would entail considerable logistic difficulties, which we chose to avoid in this first experimental study, differences in nausea responses to the two beverages would confirm the conditioning hypothesis. This experimental approach would allow formal testing of a number of issues in human classical conditioning under circumstances that may CONDITIONED NAUSEA DURING CHEMOTHERAPY have clinical significance. For example, our data suggest that the conditioning concept of latent inhibition, which originated in laboratory research with animals (23), may be relevant to the development of conditioned nausea to a beverage paired with chemotherapy. If our post hoc observations can be confirmed in an experimental study in which patients are deliberately pre-exposed to the conditioned stimulus, the conditioned nausea paradigm could provide the solid evidence for latent inhibition that has been lacking in previous conditioning research with humans (24) .
The nausea response to the beverage paired with chemotherapy highlights the opportunities for the study of human classical conditioning provided by this potent medical treatment. Within this clinical context, the pairing of a distinctive beverage with chemotherapy allowed experimental analysis of conditioned responses that might be difficult to achieve in the laboratory. Moreover, the experimentally conditioned nausea response provides a model of anticipatory nausea and thereby facilitates the development of clinical interventions. 
